All In Biotech

Free tool

FAERS Monitor: Tagamet Hb

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 21, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 020238 or its brand name (Tagamet Hb, Cimetidine). Reports on generic versions are filed under their own applications.

Reports

9,313

Serious

7,592

82% of reports

Hospitalization

3,450

Death reported

1,182

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • chronic kidney disease1,264
  • acute kidney injury716
  • nausea698
  • renal failure694
  • fatigue606
  • drug ineffective510
  • dyspnoea507
  • vomiting493
  • diarrhoea454
  • pain439
  • death403
  • dizziness388
  • off label use387
  • headache373
  • gastrooesophageal reflux disease369

Reports by year received

View as table
YearReports
2004351
2005479
2006351
2007186
2008275
2009279
2010321
2011368
2012647
2013288
2014222
2015349
2016348
2017350
2018685
20191,032
2020599
2021590
2022449
2023377
2024314
2025265
2026185

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,044,846 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
chronic kidney diseaseSignal1,26438.236.345,142
renal failureSignal69411.911.06,898
acute kidney injurySignal71610.69.96,240
gastrooesophageal reflux diseaseSignal36910.49.43,121
vomitingSignal4932.42.2397
dyspnoeaSignal5072.01.9268
nausea6982.01.9357
fatigue6061.81.6205
dizziness3881.81.6129
pain4391.61.5105
diarrhoea4541.61.5102
headache3731.31.233
death4031.11.01
off label use3871.00.90
drug ineffective5100.90.810

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.